丙戊酸盐通过优先靶向HDAC2逆转小鼠躁狂样行为
该临床前研究利用小鼠模型探究丙戊酸盐(VPA)治疗双相障碍的治疗靶点。研究发现组蛋白去乙酰化酶(HDAC)抑制剂可 normalize 躁狂样行为,其中I类HDAC(HDAC1和HDAC2)最为重要;通过RNAi技术,在腹侧被盖区(VTA)抑制HDAC2而非HDAC1足以恢复行为,且VTA中HDAC2过表达可阻断VPA的作用。结合小鼠和双相障碍患者诱导多能干细胞(iPSCs)的RNA测序,进一步确定了HDAC2及其下游靶点作为开发新型抗躁狂疗法的潜在目标。
要点
- HDAC抑制剂可改善小鼠躁狂样行为,I类HDAC(HDAC1/2)起关键作用
- VTA中抑制HDAC2而非HDAC1足以逆转行为,HDAC2过表达阻断VPA效应
- HDAC2及其下游分子是开发双相躁狂新疗法的潜在靶点
核心结论
- 丙戊酸盐通过优先靶向HDAC2发挥抗躁狂样行为作用。
研究设计与样本
- 临床前小鼠模型研究,结合RNAi和RNA测序,并纳入双相障碍患者来源的iPSCs。
主要发现
- HDAC抑制剂可 normalize 小鼠躁狂样行为,I类HDAC(HDAC1和HDAC2)最为重要。
- VTA中抑制HDAC2而非HDAC1足以恢复行为,HDAC2过表达则阻断VPA作用。
- 小鼠与双相患者iPSCs的RNA测序进一步识别了HDAC2下游分子靶点。
临床怎么用
- 提示HDAC2及其下游通路可作为双相躁狂新型治疗药物的开发靶点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Valproate (VPA) has been used in the treatment of bipolar disorder since the 1990s. However, the therapeutic targets of VPA have remained elusive. Here we employ a preclinical model to identify the therapeutic targets of VPA. We find compounds that inhibit histone deacetylase proteins (HDACs) are effective in normalizing manic-like behavior, and that class I HDACs (e.g., HDAC1 and HDAC2) are most important in this response. Using an RNAi approach, we find that HDAC2, but not HDAC1, inhibition in the ventral tegmental area (VTA) is sufficient to normalize behavior. Furthermore, HDAC2 overexpression in the VTA prevents the actions of VPA. We used RNA sequencing in both mice and human induced pluripotent stem cells (iPSCs) derived from bipolar patients to further identify important molecular targets. Together, these studies identify HDAC2 and downstream targets for the development of novel therapeutics for bipolar mania.
引用
- Logan RW, Ozburn AR, Arey RN, et al. Valproate reverses mania-like behaviors in mice via preferential targeting of HDAC2. Mol Psychiatry. 2020. PMID: 33235333. doi:10.1038/s41380-020-00958-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。